What's coming at ASCO

It's still two weeks from the start of the biggest oncology meeting of the year, but the ASCO (American Society of Clinical Oncology) committee has chosen six abstracts to be released to the public before the start of the meeting in June 4. The abstracts included:

1) A study showed that a four-week gentle yoga program improved fatigue, sleep quality, and general quality of life in women cancer survivors. (Read "Yoga helps fatigue, sleep in cancer survivors.")

2) Two separate studies determined that maintenance treatment is useful in follicular lymphoma and myeloma. Maintenance treatment with Rituxan in follicular lymphoma reduces the risk of recurrence, while treatment with Revlimid delays disease progression in myeloma. (Read "Rituxan halves risk of lymphoma recurrence"; "Celgene's Revlimid positive in maintenance trials.")

3) Scientists found gene variants that increase the risk of heart failure with anthracyclines in childhood cancer patients. The finding could help physicians determine treatment strategies for patients and develop individual survivorship plans that screen for late effects of cardiac toxicity. (Read "Genes predict anthracyclines cardiotoxicity.")

4) A promising screening strategy to detect early-stage ovarian cancer was announced that includes annual CA-125 testing in post-menopausal women at average risk. (Read "New approach to old test may detect ovarian cancer.")

Internal server error